Table 1.
Baseline demographics of both patient groups
| Patients with epirubicin-based chemotherapy (n = 39) | Patients with left-sided radiotherapy (n = 27) | p value | |
|---|---|---|---|
| Demographics | |||
| Age, yrs | 51 ± 11 | 56 ± 14 | 0.08 |
| Weight, kg | 77 ± 15 | 69 ± 9 | 0.02 |
| Height, m | 1.68 ± 0.07 | 1.68 ± 0.07 | 0.72 |
| BMI, kg/m2 | 27 ± 5 | 25 ± 3 | 0.03 |
| BSA, m2 | 1.86 ± 0.18 | 1.78 ± 0.13 | 0.04 |
| Cancer stage | |||
| DCIS, n (%) | 0 (0) | 4 (15) | 0.024 |
| T1, n (%) | 8 (21) | 17 (63) | 0.028 |
| T2, n (%) | 25 (64) | 6 (22) | 0.001 |
| T3, n (%) | 2 (5) | 0 (0) | 0.51 |
| T4, n (%) | 4 (10) | 0 (0) | 0.14 |
| N0, n (%) | 18 (46) | 24 (89) | < 0.001 |
| N1, n (%) | 21 (54) | 2 (7) | < 0.0001 |
| N2, n (%) | 0 (0) | 1 (4) | 0.41 |
| N3, n (%) | 0 (0) | 0 (0) | > 0.99 |
| M0, n (%) | 39 (100) | 27 (100) | > 0.99 |
| M1, n (%) | 0 (0) | 0 (0) | > 0.99 |
| Cardiovascular risk factors | |||
| Hypertension, n (%) | 6 (15) | 10 (37) | 0.08 |
| Diabetes, n (%) | 0 (0) | 1 (4) | 0.41 |
| Dyslipidemia, n (%) | 1 (3) | 2 (7) | 0.56 |
| Current smoking, n (%) | 4 (10) | 1 (4) | 0.64 |
| Family history of CAD, n (%) | 3 (8) | 2 (7) | > 0.99 |
| Known CAD, n (%) | 1 (3) | 1 (4) | > 0.99 |
| Cardiac medication | |||
| Aspirin/clopidogrel, n (%) | 1 (3) | 3 (11) | 0.30 |
| Statins, n (%) | 1 (3) | 2 (7) | 0.56 |
| Beta-blockers, n (%) | 4 (10) | 3 (11) | > 0.99 |
| ACEI or ARB, n (%) | 6 (15) | 6 (22) | 0.53 |
| Laboratory tests | |||
| HS TNT, pg/ml | 5 ± 4 | 5 ± 2 | 0.68 |
| NT-proBNP, pg/ml | 121 ± 118 | 98 ± 85 | 0.40 |
| Hematocrit, % | 37 ± 4 | 37 ± 3 | 0.96 |
| Hb, mg/dl | 12.5 ± 1.1 | 12.7 ± 1.0 | 0.54 |
| Creatinine, mg/dl | 0.82 ± 0.2 | 0.77 ± 0.12 | 0.20 |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BSA, body surface area; CAD, coronary artery disease; Hb, hemoglobin; HS TNT, high sensitive troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide